GILD

Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying the Inflation Reduction Act and other drug pricing

Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development.

Issues related to drug pricing

Issues pertaining to the 340B drug discount program. Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations

Prescription drug payment reform. Supply Chain. 340B Program. Implementation of Inflation Reduction Act of 2022. General HIV policy.

federal budget issues IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization Medicare & Medicaid payment and coverage issues

Issues related to regulation of prescription drugs and biologics

Legislative services related to corporate and international tax matters.

Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.